A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex

This study has been completed.

Study NCT00002246. Last updated on October 1, 2007. Information provided by Bristol-Myers Squibb

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields

Brief Title ^†

A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex

Official Title ^†

A Pilot Open Label, Multicenter Study to Evaluate the Role of Stavudine (d4T) in the Treatment of AIDS Dementia Complex

Brief Summary

The purpose of this study is to see if adding stavudine (d4T) to anti-HIV drug regimens (with or without zidovudine, ZDV) can improve symptoms of AIDS Dementia Complex (ADC, problems involving the brain or spinal cord) in HIV-positive patients.

Detailed Description

In this open-label, multicenter, multinational study, ZDV is replaced with d4T in ZDV-containing regimens, or d4T is added to non-ZDV-containing regimens in 20 patients experiencing ADC. Patients are defined as having failed treatment if they progress by one ADC stage on the MSK (Memorial Sloan Kettering) rating scale on study (i.e., from Stage 1 to 2 or Stage 2 to 3). Patients are evaluated on a weekly basis until the dementia deterioration is confirmed to be caused by HIV-1. The effect of d4T-containing regimens is assessed for the following parameters: neurological status, survival, AIDS-defining conditions, CSF (cerebrospinal fluid) and plasma viral load, CSF and blood immunological markers, blood CD4 cell counts, and viral resistance. This study also assesses the pharmacokinetics of d4T in the CSF and in the blood.

Study Phase

Phase III

Study Type ^†

Interventional

Study Design ^†

Treatment, Pharmacokinetics Study

Primary Outcome Measure ^†

Secondary Outcome Measure ^†

Condition ^†

AIDS Dementia Complex
HIV Infections

Intervention ^†

Drug: Stavudine

MEDLINE PMIDs

Links

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

Recruitment Information Fields

Recruitment Status ^†

Completed

Enrollment ^†

Start Date ^†

October 1997

Completion Date

Eligibility Criteria ^†

Inclusion Criteria

You may be eligible for this study if you:

Are HIV-positive.
Are at least 13 years old (need consent if under 18).
Have AIDS Dementia Complex.
Have been on a stable anti-HIV drug regimen for at least 8 weeks prior to study entry.
Agree to use effective methods of birth control during the study.
Are available for at least 16 weeks of study.

Exclusion Criteria

You will not be eligible for this study if you:

Have ever taken d4T.
Have a neurological (brain/spinal cord) disease, such as chronic seizures or head injury, or certain other conditions that would interfere with your ability to complete the study.
Are pregnant or breast-feeding.
Abuse alcohol or drugs.
Have peripheral neuropathy or a newly diagnosed AIDS-defining infection that requires treatment at the time of study enrollment.
Have received certain medications.
Cannot take medications by mouth.
Have severe diarrhea for at least 7 days in a row within 30 days prior to study entry.

Gender

Both

Ages

13 Years and older

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States, Australia, United Kingdom

Administrative Information Fields

NCT ID ^†

NCT00002246

Organization ID

244E

Secondary IDs ^††

AI455-064

Study Sponsor ^†

Bristol-Myers Squibb

Collaborators ^††

Investigators ^†

Study Chair:

B Brew

Information Provided By

Bristol-Myers Squibb

Verification Date

October 2007

First Received Date ^†

November 2, 1999

Last Updated Date

October 1, 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.